Mircera (methoxy polyethylene glycol- epoetin beta)

Mircera is covered for anemia due to chronic kidney disease in adults (on dialysis or not) and for pediatric patients 5–17 years on hemodialysis converting from another ESA, but is not indicated for non-CKD anemia or children <5 years; approvals are for 12 months. Coverage requires documentation of CKD/dialysis status, age/weight, adequate iron stores or ongoing iron therapy, hemoglobin thresholds (initial adult not-on-dialysis <10.0 g/dL; <11.5 g/dL if already on an ESA, with pediatric conversion requiring prior hemoglobin stabilization), and specified route/dosing limits (adults SC or IV; pediatrics IV only with conversion dosing).

"Treatment of anemia associated with chronic kidney disease in adult patients on dialysis."

Sign up to see full coverage criteria, indications, and limitations.